Key Highlights Strategic Capitalization: Matador has amended the terms of its previously announced USD$100 million convertible note facility with ATW Partners, with an initial USD$10.5 million tranche signed.Exclusive Use of Proceeds: Capital will be used solely to purchase Bitcoin to drive Bitcoin-per-share (BPS) growth.Institutional Partnership: ATW is a leading U.S.-based institutional investor focused on innovative growth-stage financing.Scalable Structure: Convertible note structure allows for equity-a ...

FRISCO, TX, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Comstock Resources, Inc. ("Comstock" or the "Company") (NYSE; NYSE Texas: CRK) today reported financial and operating results for the quarter ended September 30, 2025. Highlights of 2025's Third Quarter Higher natural gas prices in the third quarter drove improved financial results in the quarter. Natural gas and oil sales, including realized hedging gains, were $335 million for the quarter.Operating cash flow was $190 million or $0.65 per diluted share.Adjusted ...

TEANECK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bogota Financial Corp. (NASDAQ: BSBK) (the “Company”), the holding company for Bogota Savings Bank (the “Bank”), reported net income for the three months ended September 30, 2025 of $455,000, or $0.04 per basic and diluted share, compared to a net loss of $367,000, or $0.03 per basic and diluted share, for the comparable prior year period. The Company reported net income for the nine months ended September 30, 2025 of $1.4 million, or $0.11 per basic and dilu ...

WESTPORT, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI”) announced today that its senior secured lender group has extended to November 10, 2025 the due date for CODI to publish its restated financial results for the fiscal years ended December 31, 2022, 2023 and 2024. CODI is in active conversations with its senior lender group regarding a formal forbearance extension that will provide additional time to complete the restatement process. This extension is expected to be f ...

NEWBURYPORT, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $16.4 million or $2.11 per diluted common share outstanding for its third quarter ended September 30, 2025, the same as in Q3 of 2024. Adjusted earnings per diluted share outstanding for the third quarter ended September 30, 2025, was $2.39. Sales for the third quarter ...

Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q3 2024 Raising full-year 2025 revenue guidance to $327-335 million from $310-320 million Announced launch of AdvanceAD-Tx™, the Company’s test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD) Conference call and w ...

Conference Call and Webcast scheduled for tomorrow, November 4, 2025 at 10:00 am PTSAN JUAN CAPISTRANO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign(TM) group of companies, which provide post-acute healthcare services and invest in the long-term healthcare industry, primarily in skilled nursing and senior living facilities, announced operating results for the third quarter of 2025, reporting GAAP diluted earnings per share of $1.42 and adj ...

MALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of William (“Bill”) Plovanic, CFA, to its Board of Directors. Mr. Plovanic brings a distinctive combination of capital markets expertise and operational leadership in medical technology. He currently serves as Managing Dir ...

The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET Initial safety data for 32 patients with autoimmune disease treated with AlloNK + monoclonal antibody (mAb) therapy, highlighting a favorable tolerability profile observed to date and the feasibility of patient management in outpatient rheumatology clinics Initial translational data highlighting uniform, consistent, deep B-cell depletion supporting AlloNK’s intended mechanism of action SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ...

公司业绩概览 - 2025年第三季度总收入同比增长20%至1.739亿美元 [5][6] - 第三季度GAAP净利润创纪录地同比增长63%至1890万美元 [5][6] - 第三季度调整后EBITDA创纪录地同比增长33%至2510万美元 [5][6] - 2025年前九个月总收入同比增长41%至4.972亿美元 [12][19] 各业务板块收入表现 - 汽车保险业务收入同比增长21.3%至1.576亿美元 [6][19] - 家庭和租客保险业务收入同比增长15.2%至1630万美元 [6][19] - 其他业务收入同比下降97.7%至9000美元 [19] 市场营销与运营效率 - 可变营销支出同比增长14.1%至5010万美元 [6][19] - 运营收入同比增长50.4%至1750万美元 [19] - 调整后EBITDA利润率扩大至14.4% [6] 资本配置与财务状况 - 公司执行了2100万美元的股票回购计划，回购90万股A类普通股 [2][6] - 季度末现金及现金等价物为1.458亿美元 [6][14] - 总资产从2024年底的2.105亿美元增长至2025年9月30日的2.561亿美元 [14] 战略方向与管理层评论 - 公司正从潜在客户生成供应商转型为多产品、人工智能驱动的盈利增长解决方案提供商 [2] - 通过更广泛地应用机器学习和人工智能技术，推动业务转型并取得显著进展 [2] - 管理层对EverQuote产生长期可持续增长和自由现金流的能力充满信心 [2] 2025年第四季度业绩展望 - 预计收入在1.74亿至1.8亿美元之间，中点同比增长20% [6] - 预计可变营销支出在4600万至4800万美元之间，中点同比增长7% [6] - 预计调整后EBITDA在2100万至2300万美元之间，中点同比增长16% [6]